EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Assurance methods for designing a clinical trial with a delayed treatment effect

James A Salsbury iD, Jeremy E Oakley, Steven A Julious iD, Lisa V Hampson

Statistics in Medicine · 2024

DOI: 10.1002/sim.10136 ↗

At a glance

Journal article in Statistics in Medicine, 2024. Written by James A Salsbury and 3 co-authors. Institution: The School of Mathematics and Statistics, The University of Sheffield, Sheffield, UK. Major MEDLINE topics: Bayes Theorem, Research Design. Cited 7 times so far (Crossref); 54 references. The full text is freely available (open access, CC BY 4.0). Funded by: Engineering and Physical Sciences Research Council.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

An assurance calculation is a Bayesian alternative to a power calculation. One may be performed to aid the planning of a clinical trial, specifically setting the sample size or to support decisions about whether or not to perform a study. Immuno‐oncology is a rapidly evolving area in the development of anticancer drugs. A common phenomenon that arises in trials of such drugs is one of delayed treatment effects, that is, there is a delay in the separation of the survival curves. To calculate assurance for a trial in which a delayed treatment effect is likely to be present, uncertainty about key parameters needs to be considered. If uncertainty is not considered, the number of patients recruited may not be enough to ensure we have adequate statistical power to detect a clinically relevant treatment effect and the risk of an unsuccessful trial is increased. We present a new elicitation technique for when a delayed treatment effect is likely and show how to compute assurance using these elicited prior distributions. We provide an example to illustrate how this can be used in practice and develop open‐source software to implement our methods. Our methodology has the potential to improve the success rate and efficiency of Phase III trials in immuno‐oncology and for other treatments where a delayed treatment effect is expected to occur.

Subjects

MeSH terms (MEDLINE)

Bayes TheoremResearch DesignHumansSample SizeModels, StatisticalNeoplasmsClinical Trials, Phase III as TopicClinical Trials as TopicComputer SimulationAntineoplastic AgentsTime FactorsSurvival AnalysisTreatment Delay

Author keywords

assurancedelayed treatment effectsexpert judgementprior elicitationprobability of success

Substances

Antineoplastic Agents

Authors and institutions

  • The School of Mathematics and Statistics, The University of Sheffield, Sheffield, UK.
  • The School of Health and Related Research, The University of Sheffield, Sheffield, UK.
  • Advanced Methodology and Data Science, Novartis Pharma AG, Basel, Switzerland.

ORCID profiles: James A Salsbury, Steven A Julious

Funding

  • Engineering and Physical Sciences Research Council

Cite

APA

Salsbury, J. A., Oakley, J. E., Julious, S. A., & Hampson, L. V. (2024). Assurance methods for designing a clinical trial with a delayed treatment effect. Statistics in Medicine. https://doi.org/10.1002/sim.10136

Vancouver

Salsbury JA, Oakley JE, Julious SA, Hampson LV. Assurance methods for designing a clinical trial with a delayed treatment effect. Statistics in Medicine. 2024. doi:10.1002/sim.10136

BibTeX
@article{Salsbury2024,
  author = {Salsbury, James A and Oakley, Jeremy E and Julious, Steven A and Hampson, Lisa V},
  title = {Assurance methods for designing a clinical trial with a delayed treatment effect},
  journal = {Statistics in Medicine},
  year = {2024},
  doi = {10.1002/sim.10136}
}
Start for free →